<DOC>
	<DOCNO>NCT01633099</DOCNO>
	<brief_summary>The purpose study confirm safety therapeutic effect Decitabine treatment elderly Acute Myeloid Leukemia ( AML ) patient .</brief_summary>
	<brief_title>Therapeutic Effect Safety Study Decitabine Elderly Acute Myeloid Leukemia Patients</brief_title>
	<detailed_description>The outcome elderly AML patient poor . No obvious progress achieve field . Decitabine kind specific DNA methylation shift enzyme inhibitor . It reverse DNA methylation induce differentiation apoptosis tumor cell . Recent study decitabine treatment elderly AML patient achieve inspiring result indicate low dose decitabine maybe good choice elderly AML patient . So research investigator plan evaluate safety therapeutic effect decitabine treatment elderly AML patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Clinical diagnosis acute myeloid leukemia.De novo secondary AML . 2 . Age &gt; = 60years , female male . 3 . Before enrollment，WBC &lt; 40×10E9/L，Plt &gt; 20×10E9/L（Hydroxyurea permitted.） 4 . In 2 week enrollment，total bilirubin &lt; 1.5×ULN，ALT &lt; 2.5×ULN；GGT &lt; 2.5×ULN ，Scr &lt; 2.0×ULN creatinine clearance rate ≥ 50 ml/min（CockroftGault） . 5 . Before enrollment，patients must free toxicity cause former treatment.Received chemotherapy last 4 week nitrosourea last 6 week . 6 . Contraception must take avoid pregnancy study . 7 . ECOG 0,1 , 2 , predict lifetime longer 12 week . 8 . Patients must sign informed consent prior study related screening procedure perform . 1 . Acute promyelocytic leukemia . 2 . Chromosome genetic abnormality relate t（8 ; 21）、inv（16）、t（15 ; 17） . 3 . Central nervous system leukemia . 4 . Bone marrow dry tap . 5 . Patients receive stem cell transplantation chemotherapy contain azacitidine , cytarabine decitabine last one year , radiation therapy last 14 day , lenalidomide 30 day include . 6 . Patients suffer autoimmune hemolytic anemia immune thrombocytopenia . 7 . Patients suffer nonleukemia related comorbidities cause dysfunction organ . 8 . Patients suffer unstable angina （NYHA）3/4 Congestive heart failure . 9 . Patients suffer chronic respiratory disease need continued oxygen . 10 . Other active malignancy . 11 . Active HBV , HCV AIDS patient . 12 . Uncontrolled virus bacterium infection . 13 . The investigator believe patient suitable trial . 14 . Severe mental body disorder interfere research uncontrolled heart , lung disease , diabetes , etc . 15 . Allergic decitabine accessory . 16 . Patients receive research last 30 day . 17 . Without contraception . 18 . Complications cause organ dysfunction cause AML .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>decitabine</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>elderly patient</keyword>
</DOC>